1	Possible association of nucleobindin-1 protein with
2	depressive disorder in patients with HIV infection
3	
4	Yun Yang ¹ , Qian Zhang ¹ , Jing Yang ¹ , Yun Wang ¹ , Ke Zhuang ^{2*} Changcheng Zhao ^{1*}
5	
6	1. The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and
7	Technology of China, Hefei, Anhui, 230022, China;
8	2. ABSL - III Laboratory at the Center for Animal Experiment, State Key Laboratory of Virology, Wuhan
9	University, Wuhan, Hubei, 430071, China
10	
11	* Corresponding author
12	E-mail: 00008238@whu.edu.cn and zccand@163.com
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract

24	Objective To investigate the prevalence for depressive disorder among HIV-infected population and preliminarily
25	explore the underlying mechanisms. Methods Individuals who were newly HIV diagnosed were assessed on the
26	Hospital Anxiety and Depression scale (HAD-A and HAD-D). Then SHIV-infected rhesus monkey model was
27	used to investigate the possible involvement of NUCB1 and CB1 protein in depression-like behavior. Results The
28	prevalence rate of depression disorder among newly confirmed HIV cases was 27.33% (41/150). The mechanism
29	research results showed elevated NUCB1 levels in cerebrospinal fluid (CSF) from HIV-infected patients suffering
30	from depression were confirmed by western blotting compared to those of HIV-infected patients. Also,
31	immunohistochemical analysis indicated expression of NUCB1 in the cerebral cortex neurons of SHIV-infected
32	monkey was higher than that of healthy control. Conversely, CB1 expression were down-regulated at protein level.
33	Conclusions Depression are common in HIV infection and associate with NUCB1 expression increase, and
34	NUCB1 may be a potential target for depression among HIV-infected subjects.
35	
	T , N , N

36 Introduction

Depression is common in human immunodeficiency virus (HIV) infection ^{[1][2]}. Studies showed that
HIV is a direct and indirect causes of depression. In recent years, the researches that explore possible
mechanisms underlying depression among people living with HIV/AIDS (PLWHA), thereby
discovering new diagnostic markers and novel therapeutic targets, have become hotspots in the field
of both AIDS and neurobiology research.

HIV can enter central nervous system. A paper indicated that an adult-viable mutant that completely 42 43 disrupts the G protein α -subunit binding and activating motif of nucleobindin 1 (NUCB1)^[3], has been shown to play a neuroprotective role in Drosophila model of neurodegenerative disease. 44 45 Besides, in 2020, a LC-MS/MS analysis predicted that a significantly positive correlation between plasma protein levels of NUCB1 and degree of depression ^[4]. Therefore, we put forward the 46 47 hypotheses that alterations in NUCB1 expression might be linked to depression among PLWHA. The present study aimed to survey the prevalence for depression disorder among PLWHA and 48 49 preliminarily explore the underlying mechanisms. Considering simian immunodeficiency virus 50 (SIV) or simian / human immunodeficiency virus (SHIV) infected rhesus macaques (RMs) have

51 been widely utilized in pathogenic mechanisms of neuroAIDS ^{[5][6]}, to unravel the possible

52 involvement of NUCB1 in the pathophysiology of depression among PLWHA, SHIV infection in 53 RMs induces virus replication and affects pathological changes in the brain that resembles that of 54 humans. Understanding of the mechanism underlying the interaction between NUCB1 expression 55 and depression in the context of HIV-infection may provide insights that may facilitate the 56 development of biomarker for diagnosis, new drug target, and treatment response.

57

58 Material and Methods

59 Research subjects

60 In order to eliminate the potential effects of other factors, from January 2015 to October 2020, a

total of 150 HIV/AIDS individuals newly confirmed by positive HIV viral load, positive antibody

62 testing (ELISA and western blot), were selected at the First Affiliated Hospital of the University

63 of Science and Technology of China (USTC). All participants were asked to participate in The

64 Hospital Anxiety and Depression (HAD) scale questionnaires and the medical history systems.

This study has been reviewed and approved by the Bioethics and Biological Safety Review

66 Committee of USTC (2021-N(H)-236).

67 Investigation Procedures

68 HAD scale was used to assess severity of anxiety and depression symptoms, where A represents

anxiety, while D represents depression. The score of each subscale ranges between 0 and 21

points. Overall, the total scores of HAD-A and HAD-D were classified as normal (0 - 7) and

anxiety or depressive (8 - 21) with higher scores indicating higher levels of symptoms.

72 Western Blot Assay

Night cerebrospinal fluid (CSF) samples (HAD-D score ≥ 16) were obtained by lumbar puncture

in the morning. 3 mL CSF was taken from each subject. Western blot was performed as previously

described ^[7]. Briefly, Proteins in 500 μl CSF sample were separated by SDS-PAGE and

transferred onto nitrocellulose membranes. After blocking with 5% milk for 1 h, membranes were

incubated with primary antibodies (anti-NUCB1 Rabbit pAb, ABclonal, A3994) at 4°C overnight.

78 Appropriate secondary antibodies (1:2000, Santa Cruz) were used for two-hour incubation at room

- temperature. Membranes were visualized by ECL plus kit (GE Healthcare and Life Science).
- 80 Animals and Ethics Statement

81 The RMs used in this study were from the Tiangin Breeding and Research Center (SCXK (e) 82 2021-0010), Hubei Province, China. The monkeys were housed in an air-conditioned room with 83 an ambient temperature of 16-26°C, a relative humidity of 40-70% and a 12-hour light-dark cycle at the Animal Bio-Safety Level-III laboratory of the Wuhan University (SCXK (e) 2019-0013). 84 The RMs were individually housed in stainless steel wire-bottomed cages with sufficient space 85 86 (800 mm wide, 800 mm depth and 1600 mm height) and provided with a commercial monkey 87 diet. In addition to animal health was monitored daily by the animal care staff and veterinary 88 personnel. All study protocols were approved by the Institutional Animal Care and Use 89 Committee of USTC (2021-N(A) -349) in accordance with the regulations of the National Institute 90 of Health "Guide for the Care and Use of Laboratory Animals" and all details of animal welfare 91 and steps taken to ameliorate suffering were in accordance with the recommendations of the 92 Weatherall report, "The use of nonhuman primates in research". 93 Virus inoculation and sample collection 94 Seven Chinese-origin RMs from three different projects were enrolled in this study. Of these, five

95 RMs were inoculated with 10^3 - 10^8 TCID₅₀ of SIV/SHIV by either intravenous or intravaginal 96 route under anesthesia with intramuscular injection of ketamine hydrochloride (10 mg/kg) plus 97 intramuscular injection of atropine (0.04 mg/kg), while two healthy RMs were used as negative 98 controls.

99 Histology and Immunohistochemistry

100 At day of sacrifice, a depressive monkey and a healthy control were anesthetized with ketamine-101 HCl and euthanized by intravenous pentobarbital overdose. Formalin-fixed, paraffin-102 embedded brain sections from the cerebrum had been obtained, 4 microns sections were processed 103 and stained with hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC). For IHC, 104 sections were done using an automated system, the Dako Autostainer Link. Formalin-fixed paraffin 105 sections were rehydrated with water. Heat-induced epitope retrieval was performed with the FLEX 106 TRS High-pH Retrieval Buffer for 20 minutes. After peroxidase blocking, the specific monoclonal 107 antibody (IHC-plus CNR1/CB1 pAb, Lifespan, LS-B8253; anti-NUCB1 Rabbit pAb, ABclonal, 108 A3994) was applied at room temperature for 20 minutes. The FLEX + Rabbit EnVision System was 109 used for detection. DAB chromogen was then applied for 10 minutes. Slides were counterstained 110 with Mayers hematoxylin for 5 seconds and then dehydrated and coverslipped. Images were then

111 processed and analyzed using CaseViewer software (2.1v, 3D Histech Ltd, Budapest, Hungary).

112 Negative controls were included in the run.

113 Western blotting

- 114 Western blotting was performed in cerebral cortex tissue lysates, as previously described. Briefly,
- 115 CD8b cells from SHIV-infected RMs were lysed with radioimmune precipitation assay buffer.
- 116 Subsequently, proteins were transferred onto nitrocellulose membranes (Bio-Rad), and appropriate
- 117 primary antibodies and HRP-conjugated secondary antibodies were used, and proteins were
- 118 detected with the enhanced chemiluminescent (ECL) reagent (Thermo Scientific), followed by
- 119 quantification using ImageJ software.

120 Statistical Analysis

- 121 Statistical analysis of the data was performed using chi-square test (level of significance was 0.05)
- 122 with SPSS software version 23.0 and GraphPad prism 5.0. In each aspect, univariate analysis was
- used to determine the variables significantly related to the dependent variable. The confidence

interval was 95%.

125

126 **Results**

127 Prevalence of depression among HIV-infected patients

Among 150 participants newly testing positive for HIV, 6.00 % (9/150) of patients met the criteria

for a case of depression (HAD-D score $\geq = 8$) and the prevalence of baseline anxiety was 14.00 %

- 130 (21/150) according to the HAD-A score $\geq=8$ criterion, and combined anxiety and depression
- accounts for 21.33% (32/150) of the variance in reported body dissatisfaction. Furthermore, the
- number of HIV-infected individuals with HAD-A score >= 8 was reduced significantly from 53 at
- baseline to 27 at week 8 (p = 0.006), but no statistically significant differences in the number of
- patients with HAD-D score ≥ 8 was observed comparing baseline to week 8 (p = 0.189, two
- 135 sample t-test) (See Table 1).

136 Univariate analyses of variables related to symptoms of depression among individuals with

- 137 HIV infection
- 138 We included personal information and clinical information in univariate analyses to observe
- 139 whether the variables were related to anxiety and depressive symptoms. As shown in Table 2,

among the several items, "age" and "marital status" were significantly related to the depression in

141 those patients (both p < 0.05). And, "weight" was significantly related to the patient's anxiety

142 symptom (p = 0.043) among the variables.

143 NUCB1 levels are elevated in CSF from HIV cases currently suffering from depression

CSF is a proximal fluid which communicates closely with brain tissue and contains numerous brainderived proteins. Thus NUCB1 expressions of CSF in HIV-infected individuals were examined via western blot analysis. As shown in Figure 1, comparing with only HIV cases, the protein expression of NUCB1 in the CSF was significantly increased in those HIV cases currently suffering from depression. Notably, we did not enroll a control group of healthy subjects because of the invasiveness of the CSF procedure for which the Ethics Committee did not allowed.

SHIVKU-1 infection triggers a reduction in the number of neurons in cerebral cortex ofrhesus monkey

- 152 To explore the pathogenesis of depression among PLWHA, in this study, SIV/SHIV of five RMs
- established persistent infections. Of note, during the late stage of infection, Macaque WSH01
- 154 infected with SHIV_{KU-1} presented depression-like syndromes that mimic those observed in human
- neuroAIDS, including difficulties in standing, head tilting, weakening of muscle strength,
- decreased appetite and movement, loss of body mass, ataxia, fear, psychomotor changes, sleep
- disturbance, and total loss of motoric function on the left side of the body. The animal had a slow

158 progressing course lasting for about 18 months after the triggering infection and was euthanized at

- week 72. This study demonstrated that $SHIV_{KU-1}$ infected RMs can resemble human neuroAIDS
- and will become an important tool for studying pathogenesis and evaluating treatment and
- 161 preventive drugs of neuroAIDS.

162 As shown in Figure 2, H&E staining showed marked histological damages with increased

163 infiltration and vasculitis in the brain of Macaque WSH01. Importantly, the cerebral cortex

164 exhibited a decrease in the number of neurons. Accompanied with purulent meningitis, the

- 165 intactness of cerebral cortex could be not revealed more clearly and many cavities appeared after
- 166 liquefaction of cerebral cortex tissue (Figure 2B). Specifically, the neuronal loss in the cerebral
- 167 cortex of the $SHIV_{KU-1}$ -infected monkey was observed and also substantial changes in the spatial
- arrangement of neurons. In addition, residual nerve cells bodies in the cerebral cortex changed
- 169 from swelling to shrinkage, Nissl body staining was weak, the dendritic length due to cell death or

an inflammatory process was irregular, and neural axone was thin (Figure 2b).

171 Upregulation of NUCB1 protein in cerebral cortex of SHIV_{KU-1}-infected monkey

172 We next verified whether alterations in the protein expression of NUCB1 occur in $SHIV_{KU-1}$ -

173 infected monkey via IHC staining analysis. The results revealed that, NUCB1 protein was expressed

in cerebral cortex of healthy monkey but, in the affected, the expression of NUCB1 protein was

175 higher (Figure 3). Furthermore, these findings were supported by data from quantitative Western

blotting of NUCB1 protein levels in whole cerebrum in vivo (p = 0.0056). The results suggest that

177 NUCB1 plays an important role in the pathological processes leading to depression.

178 Downregulation of CNR1 protein in cerebral cortex of SHIV_{KU-1}-infected monkey

179 Finally, 16 potential targets relative to depression were acquired from the TCMSP database

180 (https://old.tcmsp-e.com/disease.php?qd=228), and further analyzed by the online STRING

181 database (http://string.embl.de/) to explore the functional mechanism of NUCB1 protein.

182 The network showed CNR1, neuroprotective and highly expressed in the neurons ^{[8][9]}, is in close

183 contact with NUCB1 (Figure 4A). Thereby, we investigated the impact of $SHIV_{KU-1}$ infection on

184 CNR1 expression in neurons. Accordingly, we observed, using immunohistochemical technique,

the downregulation of CNR1 protein expression in the infected monkey compared to the healthy

186 control (Figure 4B and 4C). This was supported by protein levels of CNR1 via western blot analysis

187 (p = 0.0366) (Figure 4D). We speculate that decreased CNR1 expression by SHIV_{KU-1} infection

188 results in depressive disorder, because there is support for existing cannabinoid signaling pathways

190

189

191 **Discussion**

that can decrease neuronal injury^[10].

Many studies have reported significantly higher prevalence of depression in HIV-infected patients when compared to general population. In the present study the prevalence of depression among HIV-infected patients was 27.33% (41/150). Moreover, univariable logistic regression analysis indicated that age and marital status were associated with depression (p < 0.05). Unfortunately, the current diagnoses of depression are still based on clinical manifestations and self-rating scales as the main diagnostic criteria, as a lack of relevant objective laboratory indicators. Thus, there is an urgent need to search for and identify new clinical biomarkers of depression.

199 Delightfully, our understanding of the (endocannabinoid system, ECS) comprised neuromodulatory lipids and their receptors associated with depression has increased ^{[11][12]}. CNR1, also known as CB1, 200 is the most abundant G protein-coupled receptor (GPCR) in the mammalian brain. It was reported 201 that Rocha et al. ^[13] found that CNR1 knockout mice decreased weight and appetitive processes, 202 reduced rearing and exploratory behaviors, and increased anxiety, compared to wild-type littermates. 203 204 These symptoms was similar to human depression patients. In addition, a clinical phase I/II trial with SR14716A (rimonabant), a CNR1 antagonist agonist showed that it produced serious 205 206 neuropsychiatric adverse events such as anxiety, depression, and even suicidal ideation [14][15].

207 NUCB1, also known as CALNUC or NUC, is a highly conserved, multifunctional protein widely expressed in nervous cells ^[16]. Herein, down-regulation of CNR1 expression and up-regulation 208 NUCB1 expression in neurons were found in the co-occurrence of depression disorder and SHIV 209 210 infection, as detected by IHC and Western blot. Several studies has been showed that HIV gp120 211 stimulates increased cortical fatty acid amide hydrolase (FAAH), subsequently allows for rapid 2-AG and AEA production ^[17], selective ligands for the NUCB1 linked to degree of depressive 212 213 behavior ^[18], in postsynaptic neuron. Whereas the decreased CNR1 expression promote the release 214 of 2-AG and AEA^[19]. Based on our experimental research and the published data, we propose that 215 a schematic presentation of a possible mechanism of NUCB1 involvement in depression in PLWH (Figure 5). A published article indicated that ZiBuPiYin recipe, which was recorded in the book of 216 Bujuji written by Cheng Wu in the Qing dynasty, prevents and treats diabetes-associated cognitive 217 218 decline by regulating the NUCB1 protein level ^[20]. Whether the recipe, through the similar 219 molecular pathways, relieves depressive disorder in PLWHA remains to be further investigated. 220 There are several limitations in our study. Firstly, further studies are needed to demonstrate the 221 expression of NUCB1 in both selective brain areas and specific neuronal subpopulations. Also, 222 animal model, unable to conduct questionnaires, interviews, or oral reports, cannot be quantified 223 the severities of depression. Third, there is no way for a human investigator to really know 224 whether a monkey is feeling depressed. What we can do is observe the behavioral that a monkey makes to viral infection. Finally, there's too little data on NUCB1 levels in CSF from HIV-225 226 infected individuals currently suffering from depression, to draw a convincing conclusion, the 227 sample size should be enlarged, etc. Despite all this, this study suggest that NUCB1 protein may

- 228 be a novel clinical biomarker for depression, and inhibiting its activity might have potential
- 229 function that predict and monitor responsiveness of treatment.
- 230

231 Acknowledgments

- 232 We thank Ying Dong, Fei Li and Ting Liu for their constant support and useful discussions.
- 233 Funding: This study was supported by Chinese Federation of Public Health foundation (GWLM202007) and
- 234 Open project of the Third People's Hospital of Shenzhen (#13). The funders had no role in study design, data
- collection and analysis, decision to publish, or preparation of the manuscript.
- 236 Conflict of Interests: The authors have declared that no competing interests exist.
- 237 Informed consent: Informed consent was obtained from all individual participants included in the study.
- 238

239 References

- Mills JC, Harman JS, Cook RL, *et al.* Comparative effectiveness of dual-action versus single-action
 antidepressants for the treatment of depression in people living with HIV/AIDS. J Affect Disord.
 2017;215:179-186.
- Algoodkar S, Kidangazhiathmana A, Rejani PP, *et al.* Prevalence and Factors associated with Depression
 among Clinically Stable People Living with HIV/AIDS on Antiretroviral Therapy. Indian J Psychol Med.
 2017;39(6):789-793.
- Balasubramanian V, Srinivasan B. Genetic analyses uncover pleiotropic compensatory roles for
 Drosophila Nucleobindin-1 in inositol trisphosphate-mediated intracellular calcium homeostasis. Genome.
 2020;63(2):61-90.
- 4. Kim EY, Ahn HS, Lee MY, *et al.* An Exploratory Pilot Study with Plasma Protein Signatures Associated
 with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks. Biomedicines.
 2020;8(11):455.
- 252 5. Omeragic A, Kayode O, Hoque MT, *et al.* Potential pharmacological approaches for the treatment of HIV253 1 associated neurocognitive disorders. Fluids Barriers CNS. 2020;17(1):42.
- Williams K, Westmoreland S, Greco J, *et al.* Magnetic resonance spectroscopy reveals that activated
 monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest. 2005 Sep;115(9):2534-45.
- Yu J, Li X, Matei N, *et al.* Ezetimibe, a NPC1L1 inhibitor, attenuates neuronal apoptosis through AMPK
 dependent autophagy activation after MCAO in rats. Exp Neurol, 2018, 307, 12–23.

- 8. Ma L, Jia J, Niu W, *et al.* Mitochondrial CB1 receptor is involved in ACEA-induced protective effects on
- 259 neurons and mitochondrial functions. Sci Rep. 2015;5:12440.
- 260 9. Schurman LD, Lichtman AH. Endocannabinoids: A Promising Impact for Traumatic Brain Injury. Front
 261 Pharmacol. 2017;8:69.
- Liu Q, Bhat M, Bowen WD, *et al.* Signaling pathways from cannabinoid receptor-1 activation to inhibition
 of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. J
- 264 Pharmacol Exp Ther. 2009;331:1062–1070.
- 265 11. Stampanoni Bassi M, Gilio L, Maffei P, *et al.* Exploiting the Multifaceted Effects of Cannabinoids on
 266 Mood to Boost Their Therapeutic Use Against Anxiety and Depression. Front Mol Neurosci. 2018;11:424.
- 267 12. Rana T, Behl T, Sehgal A, *et al.* Integrating Endocannabinoid Signalling In Depression. J Mol Neurosci.
 268 2021;71(10):2022-2034.
- 269 13. Rocha L, Cinar R, Guevara-Guzmán R, *et al.* Endocannabinoid System and Cannabinoid 1 Receptors in
 270 Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders. Front Behav
 271 Neurosci. 2020;14:52.
- 272 14. Ettaro R, Laudermilk L, Clark SD, *et al.* Behavioral assessment of rimonabant under acute and chronic
 273 conditions. Behav Brain Res. 2020;390:112697.
- Nguyen T, Thomas BF, Zhang Y. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1
 Receptor Antagonists: Current Approaches for Therapeutics Development. Curr Top Med Chem.
 2019;19(16):1418-1435.
- 277 16. Kamthan A, Kamthan M, Kumar A, *et al.* A calmodulin like EF hand protein positively regulates oxalate
 278 decarboxylase expression by interacting with E-box elements of the promoter. Sci Rep. 2015;5:14578.
- 279 17. Towe SL, Meade CS, Cloak CC, *et al.* Reciprocal Influences of HIV and Cannabinoids on the Brain and
 280 Cognitive Function. J Neuroimmune Pharmacol. 2020;15(4):765-779.
- 18. Niphakis MJ, Lum KM, Cognetta AB 3rd, *et al.* A Global Map of Lipid-Binding Proteins and Their
 Ligandability in Cells. Cell. 2015;161(7):1668-80.
- 19. Hermes DJ, Yadav-Samudrala BJ, Xu C, *et al.* GPR18 drives FAAH inhibition-induced neuroprotection
 against HIV-1 Tat-induced neurodegeneration. Exp Neurol. 20211;341:113699.
- 285 20. Xu H, Zhou W, Zhan L, et al. The ZiBuPiYin recipe regulates proteomic alterations in brain mitochondria-
- associated ER membranes caused by chronic psychological stress exposure: Implications for cognitive
 decline in Zucker diabetic fatty rats. Aging (Albany NY). 2020;12(23):23698-23726.

2	o	0
2	o	0

- 289 Figure 1 Representative image of protein levels of NUCB1. Western blotting results showed that in HIV-
- 290 infected individuals, having comorbid depression significantly increased the expression of NUCB1 in the
- cerebrospinal fluid.
- **Figure 2 H&E staining of the cerebral cortex.** A. section of the cerebral cortex of healthy monkey (50 ×); B.
- section of the cerebral cortex of the SHIV_{KU-1}-infected monkey brain $(50 \times)$; a. section of the cerebral cortex of
- healthy monkey (400 ×); b. section of the cerebral cortex of the SHIV_{KU-1}-infected monkey brain (400 ×).
- **Figure 3 NUCB1 protein expression in cerebral cortex** A. the healthy control (400 ×); B. SHIV_{KU-1}-infected
- 296 monkey (400 ×). C. Comparison of NUCB1 expression of cerebral cortex in healthy control and SHIV_{KU-1}-infected
- 297 monkey using Western blotting. In the column, from *t* test, statistically significant differences of two groups can
- 298 be determined (p = 0.0056).
- 299 Figure 4 CNR1 protein expression in both SHIV_{KU-1}-infected monkey and healthy control. A. The protein-
- 300 protein interactome networks. Blue rectangle nodes represent downregulated proteins. Red
- 301 circular nodes stand for the upregulated proteins. The lines represent the regulation of relationship
- between two nodes. B. IHC staining against CNR1 of the healthy control (400 ×); C. IHC staining against
- 303 CNR1 of $SHIV_{KU-1}$ -infected monkey (400 ×). D. Comparison of CNR1 expression of cerebral cortex in healthy
- 304 control and SHIV_{KU-1}-infected monkey using Western blotting. In the column, from *t* test, statistically significant
- differences of two groups can be determined (p = 0.0366).

306 Figure 5 Proposed model of the molecular events in NUCB1-mediated HIV comorbid depression.

- 307
- 308

Table 1 Prevalence of anxiety and depression among HIV/AIDS patients

	H	IAD-A	HAD-D		
Items	Week 0	Week 8	Week 0	Week 8	
	≤7	≥ 8	≤7	≥ 8	
Score ≤ 7	97	105	109	105	
Score ≥ 8	53	27	41	27	
x ²		7.443		1.723	
р		0.006		0.189	

309 310

Table 2. Factors associated with anxiety and depression among patients with HIV/AIDS

Factors		n	Anxiety (HAD-A ≥ 8)	χ 2	р	Depression (HAD-D ≥ 8)	χ <i>2</i>	р
Age				0.909	0.464		5.419	0.001*
	≤ 20 years	20	10			4		

21-30 years	64	24			14		
31-40 years	38	12			10		
41-50 years	14	6			6		
≥ 51 years	14	8			10		
Gender			0.025	0.876		0.423	0.517
male	146	60			43		
female	4	1			1		
Marital status			0.039	0.962		3.270	0.044*
Single	96	38			22		
married	32	16			12		
divorced/widowed	22	10			10		
Weight (kg)			3.296	0.043*		0.735	0.483
≤60	52	28			16		
61-80	84	28			28		
≥81	14	6			0		
Education			2.469	0.069		2.135	0.103
unable to read and write or	6	6			4		
primary							
secondary	40	20			14		
junior college	52	18			14		
diploma and above	52	18			12		
Occupation			1.386	0.257		0.610	0.546
permanent employee	32	16			12		
private employee	96	34			28		
student	22	10			4		
HIV transmission route			0.029	0.865		0.733	0.395
homosexual	126	52			38		
heterosexual	24	8			6		
Time elapsed from the first			0.054	0.947		0.799	0.454
positive HIV test to ART							
initiation							
≤4 week	108	44			28		
week 4-8	20	8			8		
≥ 8 week	22	8			8		
Smoking			0.010*	0.991		0.170	0.844
never	122	50			36		
≤10 cigarettes per day	20	8			6		
≥10 cigarettes per day	8	2			2		
Drinking			0.871	0.424		0.748	0.478
never	126	52			30		
occasionally	20	6			6		
≥100ml liquor per day	4	2			4		

311 note: * significant difference






Fig .2





Fig.3






Fig.4

